Progression-free probability for patients with advanced ovarian cancer following response to first-line chemotherapy
A tool to prognosticate progression-free survival outcomes in patients with newly diagnosed ovarian cancer about to commence with maintenance olaparib and bevacizumab or bevacizumab monotherapy
Predicted two year PFS
Median PFS (years)
Predicted five year PFS
Range Predictions
Best case scenario (best 10 out of 100 similar women) would be progression free for
Typical range (middle 50 of 100 similar women) would be progression-free somewhere between
Worst case scenario (worst 10 of 100 similar) women would be progression-free for
* Lower risk patients had FIGO Stage III disease who underwent upfront surgery with complete resection. Higher surgical risk was defined as those with FIGO Stage III disease who underwent upfront surgery with residual disease or who had received neoadjuvant chemotherapy, or those with stage IV disease.
Disclaimer & Privacy
The NHMRC Clinical Trials Centre (CTC) strives to keep information stored in this tool up to date, but does not guarantee the accuracy, reliability or currency of the information. Any errors in the information that are brought to our attention will be corrected as soon as possible. The CTC reserves the right to change at any time without notice any information stored in this tool.